Surf Wiki
Save to docs
general/1-pyrrolidinyl-compounds

From Surf Wiki (app.surf) — the open knowledge base

Toceranib

Chemical compound used in the treatment of tumors

Summary

Chemical compound used in the treatment of tumors

FieldValue
imageToceranib.svg
image_classskin-invert-image
image2Toceranib ball-and-stick xray 2020.png
image_class2bg-transparent
width2260
alt2Ball-and-stick model of the toceranib molecule
tradenamePalladia
Drugs.com
DailyMedIDToceranib
pregnancy_AU
routes_of_administrationBy mouth
classAntineoplastic
ATCvetyes
ATC_prefixL01
ATC_suffixEX90
legal_AU
legal_BR
legal_CARx-only
legal_DE
legal_NZ
legal_UK
legal_USRx-only
legal_EURx-only
legal_EU_comment
legal_UN
legal_status
bioavailability77%
protein_bound91%-93%
elimination_half-life16 h
index2_labelas salt
CAS_number356068-94-5
CAS_number2874819-74-6
PubChem5329106
PubChem216034840
ChemSpiderID4486268
ChemSpiderID213163443
UNII_Ref
UNII59L7Y0530C
UNII224F9PF7J3R
KEGGD08503
KEGG2D08544
ChEMBL13608
ChEMBL22103833
PDB_ligandBWC
IUPAC_name5-[(5Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrole-3-carboxamide
C22H=25F=1N=4O=2
SMILESFc1ccc2c(c1)/C(C(=O)N2)=C/c4c(c(C(=O)NCCN3CCCC3)c([nH]4)C)C
StdInChI1S/C22H25FN4O2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-6,11-12,25H,3-4,7-10H2,1-2H3,(H,24,29)(H,26,28)/b17-12-
StdInChIKeySRSGVKWWVXWSJT-ATVHPVEESA-N

| Drugs.com =

| elimination_half-life = 16 h

Toceranib (INN), sold under the brand name Palladia, is a receptor tyrosine kinase inhibitor that is used in the treatment of canine mast cell tumor also called mastocytoma. It is the first medication developed specifically for the treatment of cancer in dogs. It is used as its phosphate salt, toceranib phosphate. It was developed by SUGEN as SU11654, a sister compound to sunitinib, which was later approved for human therapies. Toceranib is a tyrosine kinase inhibitor and works in two ways: by killing tumor cells and by cutting off the blood supply to the tumor.

The most common side effects include diarrhea, decrease or loss of appetite, lameness, weight loss, and blood in the stool.

Veterinary uses

Toceranib is indicated to treat canine cutaneous (skin-based) mast cell tumors, a type of cancer responsible for about one out of five cases of canine skin tumors. It is approved to treat the tumors with or without regional lymph node involvement.

References

References

  1. (1 October 2009). "Palladia EPAR".
  2. (2009). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 62". WHO Drug Information.
  3. (June 2009). "Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision". Clinical Cancer Research.
  4. (3 June 2009). "FDA: First Drug to Treat Cancer in Dogs Approved".
  5. (22 May 2009). "Palladia New Animal Drug Application".
  6. (24 November 2006). "In Trials for New Cancer Drugs, Family Pets Are Benefiting, Too".
Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

1-pyrrolidinyl-compounds carboxamides dog-medications drugs-developed-by-pfizer fluoroarenes indoles pyrroles receptor-tyrosine-kinase-inhibitors
Want to explore this topic further?

Ask Mako anything about Toceranib — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report